SEP 26, 2016 10:51 AM PDT

Circadian Rhythm Gene Can Influence Breast Cancer Progression

Everyone knows sleep is important. Getting a good night’s sleep resets your brain, allows for efficient cell repair and aids in effective digestion. Interruptions in sleep/wake cycles, otherwise known as the circadian rhythm, have long been thought to contribute to cancer progression due to changes at the cell and tissue level.
 
Scientists at the National Cancer Institute have recently discovered that one of the circadian rhythm genes can specifically affect breast cancer metastasis. Breast cancer is one of the most common diagnoses in women in the United States, and breast cancer metastasis is the second leading cause of death in women. It is commonly known that the primary tumor is not what causes the high mortality rates in cancer; it is the metastasis of that tumor to other body parts. Metastasis can be hard to contain, and depending on the tumor type, might not have targeted therapies to treat.
Sections of myometrial muscle infiltrated by metastatic carcinoma. (Cesar A. Moran, CancerNetwork)
To complicate things even further, there are several different subtypes of malignancy that can affect tumor progression and treatment options. Two subtypes of breast cancer, ER+ (estrogen receptor-positive) and HER+ (human epidermal growth factor-positive), have targeted therapies specifically developed to these types of tumors even after they have disseminated throughout the body. These treatments target the tumor cells directly and negate the need for general therapies such as chemotherapy.

However, ER- and HER- tumor types do not respond well to these therapies and have a higher chance of metastasis and poor survival prognosis. A better understanding of the biology and genetics behind these ER- and HER- tumors would provide the basis for new targeted therapies and clinical treatments to improve the outcome of diagnosis and malignancy in these patients.
 
Studying crosses of genetically engineered mice with highly metastatic mammary tumors with those containing low frequency metastatic tumors provided gene signatures consistent with the ER- cancer subtype and led to the identification of Arntl2, a known circadian rhythm gene, as a metastatic susceptibility gene. Kent Hunter, one of the primary authors of the study and Senior Investigator at NCI, notes that this association suggests circadian rhythm plays a role in both the cause and progression of this very aggressive form of breast cancer.
Identification of the circadian rhythm Arntl2 gene and its relationship to cancer metastases (Siracusa LD, Bussard KM; 2016)
Based on mapping data from the cross, researchers genotyped an area that highlighted the Arntl2 gene as a primary cause for progressive metastasis in the mice and related cell lines. Further knockout experiments and association-based patient cohort studies were done to validate the Arntl2 gene as a causative gene to metastatic-specific cancer progression in the ER- subtype.

This study, published in PLOS Genetics, sheds light on metastasis and the many factors that enable a primary tumor to spread. Metastasis is a complicated process influenced by many factors, such as obtaining invasive and migratory abilities, gaining entry into the lymphatic system, and colonization of cells in a new environment. Given the different factors that go into cancer progression, it has become evident that there are several outside influencers and biological processes that can positively or negatively affect tumor progression.

Circadian rhythm disruption has been indicated in previous studies to increase breast cancer risk and survival rates based on epidemiological and gene expression studies. However, there have not been any causal effects shown until now. Hunter and team were able to prove that Arntl2 has a direct effect on the metastasis of ER- breast cancer. These findings provide a genetic basis for inherited susceptibility of cancer metastasis and emphasize the potential of incorporating behavioral adjustments such as more sleep and sustained sleep/wake cycles into cancer treatment.

Sources: PLOS Genetics, NCI, Reuters, Arntl2 Image
About the Author
  • I love all things science and am passionate about bringing science to the public through writing. With an M.S. in Genetics and experience in cancer research, marketing and technical writing, it is a pleasure to share the latest trends and findings in science on LabRoots.
You May Also Like
OCT 17, 2019
Cancer
OCT 17, 2019
Combining Breast and Lung Cancer Drugs to Overcome Treatment Resistance
The efforts to overcome cancer’s ability to evolve and resist treatment take many forms and comprise a vital and active branch of contemporary cancer...
OCT 17, 2019
Immunology
OCT 17, 2019
Are Bacteria Fighting Cancer For Us?
Scientists at the Sanford Burnham Prebys Medical Discovery Institute found that the RNF5 enzyme, produced by a gene in gut microbes affects tumor growth.&n...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 17, 2019
Immunology
OCT 17, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
OCT 17, 2019
Genetics & Genomics
OCT 17, 2019
Breast Cancer Drug Increases Survival for Prostate Cancer Patients
A breast cancer drug is better at treating advanced prostate cancer in some men than current therapies, a clinical trial shows....
OCT 17, 2019
Cancer
OCT 17, 2019
Blood test to detect brain cancer
Research published recently in the journal Nature Communications, a new study details the potential of a blood test that is capable of identifying brain ca...
Loading Comments...